ADA Standards of Care 2025: What Changed This Year

ADA Standards of Care 2025: What Changed This Year

Every January, the American Diabetes Association (ADA) publishes its updated Standards of Medical Care in Diabetes — the most widely used clinical guidelines for diabetes treatment in the United States. The 2025 edition, published in Diabetes Care (Volume 48, Supplement 1), includes important updates that affect how millions of people with Type 1 and Type 2 diabetes are treated. Here's what changed, what it means, and why it matters.

1. Expanded Role of GLP-1 Receptor Agonists — Now Including Heart Failure

One of the most significant 2025 updates is the expanded cardiovascular indication for GLP-1 receptor agonists (GLP-1 RAs) like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). The 2025 Standards now explicitly recommend GLP-1 RAs or GLP-1/GIP dual agonists for people with Type 2 diabetes who have established cardiovascular disease, high cardiovascular risk, or obesity-related heart failure with preserved ejection fraction (HFpEF).

This change was driven largely by the STEP-HFpEF trial, published in The New England Journal of Medicine in 2023, which showed semaglutide 2.4 mg significantly improved symptoms, exercise function, and weight in patients with HFpEF and obesity. The 2025 guidelines integrate this evidence into standard practice recommendations for the first time.

2. Continuous Glucose Monitoring (CGM) Now Recommended More Broadly

The 2025 Standards take a stronger stance on CGM access. The ADA now recommends CGM for all people with diabetes on insulin — not just those with Type 1 — and encourages discussion of CGM for anyone on sulfonylureas (which carry hypoglycemia risk). Time-in-Range (TIR) targets are reaffirmed: greater than 70% of readings between 70–180 mg/dL for most adults.

The guidelines also formally recognize the value of intermittently scanned CGM (isCGM, such as the FreeStyle Libre 3) as equivalent to real-time CGM in many clinical situations. For patients managing supplies and devices, resources like mdsdiabetes.com can help navigate CGM options covered under current insurance and Medicare guidelines.

3. Kidney Disease: Stronger Emphasis on SGLT2 Inhibitors and Finerenone

Diabetic kidney disease (DKD) management received a significant upgrade. The 2025 Standards now place SGLT2 inhibitors (such as empagliflozin and dapagliflozin) alongside ACE inhibitors/ARBs as first-line, co-equal agents for people with Type 2 diabetes and chronic kidney disease (CKD), regardless of glycemic control needs.

The nonsteroidal mineralocorticoid receptor antagonist finerenone (Kerendia) is now more prominently featured following data from the FIDELIO-DKD and FIGARO-DKD trials and the pooled FIDELITY analysis, which collectively demonstrated reduced CKD progression and cardiovascular events. The 2025 guidelines formally recommend finerenone as an add-on therapy for patients with Type 2 diabetes, CKD (eGFR ≥25), and elevated urine albumin who remain at high risk despite ACE inhibitor/ARB and SGLT2 inhibitor therapy.

4. Diabetes Distress and Mental Health — Formalized Screening

The 2025 Standards strengthen the mental health section considerably. Annual screening for diabetes distress using validated tools (such as the Problem Areas in Diabetes scale, PAID) is now a formal recommendation, not merely a suggestion. The guidelines acknowledge that diabetes distress — distinct from clinical depression — affects up to 45% of people with diabetes and directly impacts self-management and outcomes.

5. Tirzepatide's Formal Recognition in Type 1 Diabetes Adjunct Therapy

While tirzepatide is not yet FDA-approved for Type 1 diabetes, the 2025 Standards for the first time acknowledge emerging evidence supporting adjunct use of GLP-1/GIP therapies in select adults with Type 1 diabetes who have obesity or insulin resistance. The ADA notes this is an evolving area requiring individualized discussion and monitoring for diabetic ketoacidosis (DKA) risk.

Current Status (2025)

The 2025 ADA Standards are in effect now and represent the current benchmark for diabetes care across the United States. Clinicians are expected to align practice with these guidelines, though implementation timelines vary by institution. Insurance coverage for newly recommended therapies — particularly finerenone and broader CGM — continues to lag behind clinical recommendations in some cases. Patients should ask their providers directly whether they are being managed according to 2025 ADA Standards.

What This Means for Patients

• On insulin? Ask your doctor about CGM if you aren't already using it — the 2025 guidelines support it for you.
• Have kidney disease and Type 2 diabetes? Ask whether you should be on an SGLT2 inhibitor and whether finerenone is appropriate.
• Have heart failure and Type 2 diabetes? GLP-1 therapy may now be a stronger recommendation for you than before.
• Feeling burned out by diabetes? Ask your care team about formal diabetes distress screening — this is now a standard part of your annual care.
• Managing supplies and devices? Updated coverage for CGM and insulin delivery systems can be explored through resources like mdsdiabetes.com.

The Bottom Line

The ADA's 2025 Standards reflect a diabetes care landscape that is increasingly individualized, cardiovascular-focused, and technology-supported. The shift toward earlier use of kidney- and heart-protective medications — regardless of A1C — marks a philosophical evolution: diabetes care is no longer only about blood sugar. It's about protecting the whole person. Patients who haven't reviewed their treatment plan recently should bring these updates to their next appointment.